Sygnature Discovery has appointed Kieron Hall as its new Chief Commercial Officer and Board member. Kieron will play a key role in driving Sygnature Discovery’s strategic vision towards its growth goals.

He will also spearhead the development and implementation of a dynamic go-to-market strategy, designed to leverage the group’s strengths and enhance customer relationships through a responsive and scientifically driven commercial organization. 

Commenting on his appointment Kieron said, “I am excited to join Sygnature Discovery at this pivotal time as the organization readies itself for the next phase of growth. Sygnature’s reputation for scientific excellence and unwavering commitment to translating great ideas in drug discovery into clinical candidates truly sets it apart. I’m eager to apply my experience in building and leading high performing teams to drive Sygnature’s vision of becoming the leading global drug discovery CRO.”

Kieron brings a wealth of experience from the pharma services sector. In his most recent role as Chief Commercial Officer at Quotient Sciences, he successfully led the commercial team through multiple rounds of private equity-backed growth and acquisitions.

Dr. Simon Hirst, CEO of Sygnature Discovery added: “Kieron joins Sygnature at a crucial stage in the company’s expansion. His impressive track record for leading global commercial teams, scaling businesses and managing M&A integrations aligns perfectly with our commitment to building a sustainable, robust and scalable global business that prioritizes customer partnerships and scientific excellence.

“His strategic vision and proven ability to achieve outstanding business results will further strengthen Sygnature’s position at the forefront of the drug discovery market, while enhancing our reputation for delivering exceptional value to our customers.”